BC Week In Review | Oct 1, 2012
Clinical News

Prolaris regulatory update

Myriad said the Utah's Medicare administrator Noridian Administrative Services LLC (Fargo, N.D.) informed the company that it plans to add Prolaris prostate cancer diagnostic to its next draft non-covered service local coverage determination. Myriad said...
BioCentury | Nov 2, 2009
Strategy

Building Qiagen

Building Qiagen Since Peer Schatz took over as CEO in early 2004, Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) has seen its revenues and adjusted operating income grow at CAGRs of 21% and 27%, respectively. Molecular diagnostics has...
BC Week In Review | Mar 14, 2005
Company News

Cellular Genomics management update

Cellular Genomics Inc. , Branford, Conn.   Business: Genomics, Functional genomics, Proteomics   Hired: Peter Fuller as CBO, formerly SVP of business development at Molecular Staging Inc.  ...
BC Extra | Oct 25, 2004
Financial News

Qiagen meets Street EPS

Research tool supplier Qiagen (FSE:QIA; QGENF) reported third quarter EPS of $0.10, meeting the Street estimate and up 25% from $0.08 in the same period last year. QIA's earnings exclude extraordinary charges related to relocation...
BioCentury | Oct 11, 2004
Tools & Techniques

Sample immortalization

As genetic analysis has become more widely used in both research and the clinic, scarcity of sample DNA has become such a big problem that it has been given a name: DNA constraint. Qiagen N.V....
BC Week In Review | Oct 4, 2004
Company News

Molecular Staging, Qiagen deal

QIA purchased the major assets of Molecular Staging, including its multiple displacement amplification (MDA) and rolling circle amplification (RCA) technologies, in exchange for $28.5 million in cash plus $6.8 million in sales-based milestones. QIA intends...
BC Extra | Sep 27, 2004
Company News

Qiagen buys assets of Molecular Staging

Qiagen (FSE:QIA; QGENF) purchased acquired the major assets of Molecular Staging (New Haven, Conn.), including its multiple displacement amplification (MDA) and rolling circle amplification (RCA) technologies, in exchange for $28.5 million in cash plus $6.8...
BC Week In Review | Jul 26, 2004
Company News

Senesco management update

Senesco Technologies Inc. (SNT), New Brunswick, N.J.   Business: Autoimmune, Neurology   Hired: Richard Dondero as VP of R&D, formerly group leader at Molecular Staging Inc.  ...
BC Week In Review | Jan 26, 2004
Company News

Molecular Staging board of directors update

Molecular Staging Inc. , New Haven, Conn.   Business: Proteomics, Genomics, Diagnostic   Appointed: Richard Barker, former CEO of Chiron Corp. 's Chiron Diagnostics unit, as executive chairman  ...
BioCentury | Feb 10, 2003
Strategy

PCR meets GeneChips

When Roche acquired Boehringer Mannheim in 1997, the idea was to combine therapeutics and diagnostics to deliver point-of-care genotyping and, ultimately , personalized medicine. The idea was hot at the time, as Genaissance Pharmaceuticals Inc. was...
Items per page:
1 - 10 of 33
BC Week In Review | Oct 1, 2012
Clinical News

Prolaris regulatory update

Myriad said the Utah's Medicare administrator Noridian Administrative Services LLC (Fargo, N.D.) informed the company that it plans to add Prolaris prostate cancer diagnostic to its next draft non-covered service local coverage determination. Myriad said...
BioCentury | Nov 2, 2009
Strategy

Building Qiagen

Building Qiagen Since Peer Schatz took over as CEO in early 2004, Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) has seen its revenues and adjusted operating income grow at CAGRs of 21% and 27%, respectively. Molecular diagnostics has...
BC Week In Review | Mar 14, 2005
Company News

Cellular Genomics management update

Cellular Genomics Inc. , Branford, Conn.   Business: Genomics, Functional genomics, Proteomics   Hired: Peter Fuller as CBO, formerly SVP of business development at Molecular Staging Inc.  ...
BC Extra | Oct 25, 2004
Financial News

Qiagen meets Street EPS

Research tool supplier Qiagen (FSE:QIA; QGENF) reported third quarter EPS of $0.10, meeting the Street estimate and up 25% from $0.08 in the same period last year. QIA's earnings exclude extraordinary charges related to relocation...
BioCentury | Oct 11, 2004
Tools & Techniques

Sample immortalization

As genetic analysis has become more widely used in both research and the clinic, scarcity of sample DNA has become such a big problem that it has been given a name: DNA constraint. Qiagen N.V....
BC Week In Review | Oct 4, 2004
Company News

Molecular Staging, Qiagen deal

QIA purchased the major assets of Molecular Staging, including its multiple displacement amplification (MDA) and rolling circle amplification (RCA) technologies, in exchange for $28.5 million in cash plus $6.8 million in sales-based milestones. QIA intends...
BC Extra | Sep 27, 2004
Company News

Qiagen buys assets of Molecular Staging

Qiagen (FSE:QIA; QGENF) purchased acquired the major assets of Molecular Staging (New Haven, Conn.), including its multiple displacement amplification (MDA) and rolling circle amplification (RCA) technologies, in exchange for $28.5 million in cash plus $6.8...
BC Week In Review | Jul 26, 2004
Company News

Senesco management update

Senesco Technologies Inc. (SNT), New Brunswick, N.J.   Business: Autoimmune, Neurology   Hired: Richard Dondero as VP of R&D, formerly group leader at Molecular Staging Inc.  ...
BC Week In Review | Jan 26, 2004
Company News

Molecular Staging board of directors update

Molecular Staging Inc. , New Haven, Conn.   Business: Proteomics, Genomics, Diagnostic   Appointed: Richard Barker, former CEO of Chiron Corp. 's Chiron Diagnostics unit, as executive chairman  ...
BioCentury | Feb 10, 2003
Strategy

PCR meets GeneChips

When Roche acquired Boehringer Mannheim in 1997, the idea was to combine therapeutics and diagnostics to deliver point-of-care genotyping and, ultimately , personalized medicine. The idea was hot at the time, as Genaissance Pharmaceuticals Inc. was...
Items per page:
1 - 10 of 33